Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
JD Health International's 3-Year RORE % for the quarter that ended in Dec. 2025 was 27.63%.
The industry rank for JD Health International's 3-Year RORE % or its related term are showing as below:
JDHIF's 3-Year RORE % is ranked better than 75.54% of 605
companies
in the Healthcare Providers & Services industry
Industry Median: 0.74
vs JDHIF: 27.63
JD Health International (OTCPK:JDHIF) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
JD Health International 3-Year RORE % Related Terms
JD Health International 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JD Health International 3-Year RORE % Competitor Comparison
For the Pharmaceutical Retailers subindustry, JD Health International's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JD Health International 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, JD Health International's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where JD Health International's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
JD Health International (JDHIF) has a 3-Year RORE % of 27.63 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on JD Health International and its competitors. According to the industry distribution chart, JD Health International ranks #148 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 24.5%.
Is JD Health International's 3-Year RORE % too high?
JD Health International's current 3-Year RORE % is 27.63. The Healthcare Providers & Services industry median 3-Year RORE % is 0.74. JD Health International's value of 27.63 is 3633.8% above this industry median. Based on the distribution chart, JD Health International ranks #148 out of 605 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, JD Health International has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does JD Health International's 3-Year RORE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, JD Health International ranks #148 out of 605 companies for 3-Year RORE %. This places JD Health International in the top 25% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 0.74. JD Health International's value of 27.63 is 3633.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.74, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JD Health International's current 3-Year RORE % of 27.63 is 3633.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on JD Health International and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JD Health International's current 3-Year RORE % is 27.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JD Health International stock overvalued right now?
JD Health International (JDHIF) has a current 3-Year RORE % of 27.63. The stock's GF Value™ is $10.42, compared to a current price of $5.85 — trading 43.9% below its estimated fair value. The current 3-Year RORE % is 27.63 and 3633.8% above the Healthcare Providers & Services industry median of 0.74. JD Health International's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For JD Health International (JDHIF), the current 3-Year RORE % is 27.63 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JD Health International (JDHIF) Overvalued in 2026?
Based on GuruFocus' analysis, JD Health International stock appears to be undervalued.
The current stock price of $5.85 is trading 43.9% below its estimated GF Value™ of $10.42.
Key valuation signals for JDHIF:
3-Year RORE %: 27.63
GF Value™: $10.42 vs. price of $5.85 (43.9% below fair value)
Industry Position: 3633.8% above the Healthcare Providers & Services median (#148 of 605)
No single metric tells the full story. See the JDHIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health and Meituan for its e-commerce business. As of Dec. 31, 2024, the platform has over 200 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com.
90GF Score
Get the complete analysis for JDHIF
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JDHIF has been successfully added to your 
